NCT06190561已完成1 期
A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, PARALLEL DESIGN, STUDY TO EVALUATE PHARMACOKINETIC COMPARABILITY OF TWO PF-07940367 FILM-COATED TABLET FORMULATIONS ADMINISTERED AS 150 MG UNDER FASTED CONDITIONS IN HEALTHY PARTICIPANTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to 336 hours (AUC336) of PF-07940367 dose to evaluate pharmacokinetic comparability of two PF-07940367 products
研究概览
简要总结
The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream.
This study is seeking participants who are:
- Healthy male or female participants aged 18 years or older.
All participants in this study will receive PF-07940367 once by mouth. The participants may receive different tablets by mouth for PF-07940367.
The study will compare experiences of people receiving two different products of PF-07940367. This will help understand how much PF-07940367 is taken up into the blood for each product given.
Participants will take part in the study for about 112 days. During this time, participants will have to stay onsite for 5 days. There will be up to 2 additional onsite study visits and 3 remote (telephone call) study visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- •BMI of 16-32 kg/m2; and a total body weight >50 kg (110 lb).
- •Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures.
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
- •History of human immunodeficiency virus (HIV) infection, hepatitis A, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis B surface antigen (HCVAb). Hepatitis B vaccination is allowed.
- •Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •Use of prescription or nonprescription drug, dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
- •Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.
- •A positive urine drug test.
研究组 & 干预措施
Treatment A: PF-07940367 Product II
Experimental
tablet by mouth
干预措施: PF-07940367 (Drug)
Treatment B: PF-07940367 Product I
Experimental
tablet by mouth
干预措施: PF-07940367 (Drug)
结局指标
主要结局
Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to 336 hours (AUC336) of PF-07940367 dose to evaluate pharmacokinetic comparability of two PF-07940367 products
时间窗: 0 hours (pre-dose) to 336 hours post-PF-07940367 dose
次要结局
- Maximum Observed Whole Blood Concentration (Cmax) of PF-07940367 for two PF-07940367 products(0 hours (pre-dose) to 336 hours post-PF-07940367 dose)
- Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to the last quantifiable concentration (AUClast) of PF-07940367 for two PF-07940367 products(0 hours (pre-dose) to 336 hours post-PF-07940367 dose)
- Time to Maximum Observed Whole Blood Concentration (Tmax) of PF-07940367 for two PF-07940367 products(0 hours (pre-dose) to 336 hours post-PF-07940367 dose)
- Number of Participants With Clinically Significant Laboratory Abnormalities(From baseline up to 336 hours after PF-07940367 dose)
- Number of Participants With Clinically Significant Vital Signs(From baseline up to 336 hours after PF-07940367 dose)
- Number of Participants With Treatment-Emergent Adverse Events (AEs)(From baseline up to 56 days after PF-07940367 dose)
- Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings(From baseline up to 96 hours after PF-07940367 dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy AdultsHealthy ParticipantsNCT05923411Pfizer113
已完成
1 期
A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy AdultsHealthy ParticipantsNCT06393517Pfizer23
已完成
1 期
A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881Healthy VolunteersNCT04128787Agios Pharmaceuticals, Inc.36
已完成
1 期
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy SubjectsHealthyNCT01513928Pfizer12
已完成
1 期
OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTSHealthyNCT03871439Pfizer10